MindImmune Therapeutics, Inc.
PrivateLast Round
Convertible Debt
Mar 5, 2026
Est. Valuation
$22.4M
Total Funding Raised
$52.97M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
MindImmune Therapeutics, Inc. is a biotechnology company that develops antibody-based drugs and therapeutics designed to treat diseases of the central nervous system by targeting neuroinflammation.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MindImmune Therapeutics, Inc. Comparables
Compare MindImmune Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Muna Therapeutics | 80% | |
| Allyx Therapeutics, Inc. | 78% | |
| INmune Bio Inc | 76% |
MindImmune Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Mar 5, 2026 | ||||
| Series A | Nov 24, 2025 | ||||
| Grant | Jun 1, 2025 | ||||
| Series A | Jun 14, 2022 | ||||
| Grant | Jan 1, 2022 | ||||
Seed | Aug 21, 2017 |
Key People
Founding team and executive leadership
MindImmune Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A |
| Rhode Island Life Science Hub | Grant |
| The Foundation For A Better World | Series A |
| Pfizer Ventures | Series A |
| RightHill Ventures | Series A |
| Pfizer | Series A |
| Slater Technology Fund | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 61% MoM, from 1.4K to 2.3K.
- Mar 5, 2026
Raised $5M in a VC Round.
MindImmune Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MindImmune Therapeutics, Inc.'s valuation, stock price, and market status.
Is MindImmune Therapeutics, Inc. a public or private company?
MindImmune Therapeutics, Inc. is a private company.
What is the current stock price of MindImmune Therapeutics, Inc.?
MindImmune Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks MindImmune Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MindImmune Therapeutics, Inc. worth (valuation)?
MindImmune Therapeutics, Inc.'s valuation is estimated at $22.4M based on funding round data.
Can I buy MindImmune Therapeutics, Inc. stock?
MindImmune Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MindImmune Therapeutics, Inc.'s last funding round?
MindImmune Therapeutics, Inc.'s most recent funding round was Convertible Debt on March 5, 2026.
Who are the main investors in MindImmune Therapeutics, Inc.?
Key investors in MindImmune Therapeutics, Inc. include Dolby Family Ventures, Slater Technology Fund, Alzheimer's Drug Discovery Foundation.
Will MindImmune Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for MindImmune Therapeutics, Inc..
How can I track MindImmune Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in MindImmune Therapeutics, Inc.'s shares on secondary markets.